| Pair Name | Sulforaphane, Everolimus | ||
| Phytochemical Name | Sulforaphane (PubChem CID: 5350 ) | ||
| Anticancer drug Name | Everolimus (PubChem CID: 6442177 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Sulforaphane, Everolimus | |||
| Disease Info | [ICD-11: 2C94.Z] | Bladder cancer | Investigative | |
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | AKT1 | hsa207 | |
| Up-regulation | Phosphorylation | CDK1 | hsa983 | |
| Down-regulation | Phosphorylation | CDK2 | hsa1017 | |
| Down-regulation | Expression | CCNA2 | hsa890 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Phosphorylation | RICTOR | hsa253260 | |
| Up-regulation | Phosphorylation | RPTOR | hsa57521 | |
| Up-regulation | Expression | H3C14 | hsa126961 | |
| Up-regulation | Expression | HRH4 | hsa59340 | |
| Up-regulation | Expression | CDKN2D | hsa1032 | |
| Down-regulation | Expression | PSMD9 | hsa5715 | |
| In Vitro Model | RT-112 | Bladder carcinoma | Homo sapiens (Human) | CVCL_1670 |
| UM-UC-3 | Bladder carcinoma | Homo sapiens (Human) | CVCL_1783 | |
| TCCSUP | Bladder carcinoma | Homo sapiens (Human) | CVCL_1738 | |
| Result | The addition of SFN to the long-term everolimus application inhibits resistance development in bladder cancer cells in vitro. Therefore, sulforaphane may hold potential for treating bladder carcinoma in patients with resistance to an mTOR inhibitor. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. Int J Mol Sci. 2020 Jun 4;21(11):4026. doi: 10.3390/ijms21114026. | Click |
